Akuffo E L, Hunt J R, Moss J, Woodrow D, Davies M, Mason R M
Department of Biochemistry, Charing Cross and Westminster Medical School, London, UK.
Biochem J. 1996 Nov 15;320 ( Pt 1)(Pt 1):301-8. doi: 10.1042/bj3200301.
Rats were implanted with mini osmotic pumps delivering sodium [35S]sulphate and their newly synthesized proteoglycans were labelled over a 146 h period (steady-state labelling). Proteoglycan turnover was measured in vivo using a chase protocol. Glomerular proteoglycans were recovered quantitatively and the perlecan present was isolated by immunoprecipitation. The procedure allows newly synthesized proteoglycans to be quantified in mass units (pmol of glycossminoglycan sulphate) after labelling and during the chase. Ultrastructural-immunogold experiments identified the location of perlecan as the glomerular basement membrane and mesangial matrix. Perlecan in the basement membrane was quantified using the ultrastructural-immunogold technique. Perlecan comprises about 10% of the total glomerular proteoglycans, which are otherwise associated with glomerular cells and the mesangium. Both the total glomerular heparan sulphate proteoglycans and perlecan turn over rapidly (t1/2 approximately 3-4 h and < 3 h respectively). In contrast, turnover of proteoglycans in other tissues was slow, except in the liver where the heparan sulphate and chondroitin sulphate t1/2 values were 16 h and 9 h respectively. Microalbuminuria was induced with a low-dose regimen of puromycin aminonucleoside. At the onset of microalbuminuria (5 days) there was no change in the level of newly synthesized perlecan, or in perlecan in the glomerular basement membrane detected by immunogold labelling. Newly synthesized perlecan had undergone a minimal change in turnover rate by day 5 in puromycin aminonucleoside-treated rats. In contrast, the total glomerular proteoglycan population showed a dramatic decrease in turnover by day 5. Since there was no evidence of accumulation of glomerular proteoglycans on either day 5 or day 6, it is likely that decreased turnover of cell-associated proteoglycans is accompanied by an equivalent decrease in their synthesis.
给大鼠植入能输送硫酸钠[35S]的微型渗透泵,在146小时内(稳态标记)标记其新合成的蛋白聚糖。采用追踪方案在体内测量蛋白聚糖的周转。定量回收肾小球蛋白聚糖,并通过免疫沉淀分离其中存在的基底膜聚糖。该程序可在标记后和追踪期间以质量单位(硫酸糖胺聚糖的皮摩尔数)对新合成的蛋白聚糖进行定量。超微结构免疫金实验确定基底膜聚糖位于肾小球基底膜和系膜基质中。使用超微结构免疫金技术对基底膜中的基底膜聚糖进行定量。基底膜聚糖约占肾小球蛋白聚糖总量的10%,其余与肾小球细胞和系膜相关。肾小球硫酸乙酰肝素蛋白聚糖总量和基底膜聚糖的周转都很快(半衰期分别约为3 - 4小时和<3小时)。相比之下,其他组织中蛋白聚糖的周转较慢,除了肝脏,其中硫酸乙酰肝素和硫酸软骨素的半衰期分别为16小时和9小时。用低剂量嘌呤霉素氨基核苷诱导微量白蛋白尿。在微量白蛋白尿开始时(5天),新合成的基底膜聚糖水平或通过免疫金标记检测到的肾小球基底膜中的基底膜聚糖没有变化。在嘌呤霉素氨基核苷处理的大鼠中,到第5天新合成的基底膜聚糖的周转率变化最小。相比之下,到第5天肾小球蛋白聚糖总量的周转显著下降。由于在第5天和第6天都没有肾小球蛋白聚糖积累的证据,细胞相关蛋白聚糖周转率的降低可能伴随着其合成的同等程度降低。